WHITEHAWK THERAPEUTICS INC (WHWK)
Health Care · NASDAQ
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload technology.
What WHITEHAWK THERAPEUTICS INC does
Whitehawk Therapeutics is a clinical-stage oncology company focused on developing and commercializing next-generation antibody-drug conjugates (ADCs) using advanced linker-payload platforms. The company in-licensed a portfolio of three ADCs (HWK-007, HWK-016, HWK-206) from WuXi Biologics and Hangzhou DAC Biotechnology, each targeting distinct tumor antigens (PTK7, MUC16, SEZ6) in cancer indications including non-small cell lung cancer, ovarian cancer, endometrial cancer, small cell lung cancer, and neuroendocrine tumors. The company leverages deep experience in drug formulation, delivery technology, and oncology development, with Phase 1 trials already active for two lead candidates and data readouts expected in the first half of 2027.
Themes: ["ADC development / antibody-drug conjugates","Oncology / cancer therapeutics","Targeted cancer therapy","Clinical-stage therapeutics","Drug delivery technology"]
Fundamentals
- Price$3.86 as of 2026-07-09 close
- Market cap$211M as of 2026-07-10
- 1-year return+92.0% as of 2026-07-09 close
- Net margin+99.4% as of 2026-07-10
- Gross margin+88.7% as of 2026-07-10
- ROE-79.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-22.3% as of 2026-07-10
- Revenue CAGR (3y)-22.3% SEC XBRL
- Beta0.80 as of 2026-07-10
Key risks (from latest filing)
["Early-stage development risk: all three lead ADC candidates are in Phase 1 trials with data not expected until H1 2027, carrying typical clinical trial and regulatory approval uncertainties","Revenue decline and operational transition: company divested legacy FYARRO business (generating $7.1M in 2025 vs. $26.0M in 2024), creating cash burn dependence on in-licensed ADC portfolio success","Dependence on collaboration partners: success relies on WuXi Biologics for manufacturing and development of in-licensed ADCs, with execution risk dependent on third-party partners"]
Competitors & peers
- Seagen (SGEN)
- Pfizer (PFE)
- Genmab (GMAB)
- Astellas Pharma (ASPH)
- Gilead Sciences (GILD)
- ImmunoMedics (now Gilead subsidiary)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.